April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
Predicting Glaucomatous Progression from Baseline HRT and SAP Measurements Using Relevance Vector Machine (RVM) Classifiers
Author Affiliations & Notes
  • Christopher Bowd
    Hamilton Glaucoma Center, Dept. of Ophthalmology, University of California, San Diego, California
  • Intae Lee
    Hamilton Glaucoma Center, Dept. of Ophthalmology, University of California, San Diego, California
  • Felipe A. Medeiros
    Hamilton Glaucoma Center, Dept. of Ophthalmology, University of California, San Diego, California
  • Madhusudhanan Balasubramanian
    Hamilton Glaucoma Center, Dept. of Ophthalmology, University of California, San Diego, California
  • Linda M. Zangwill
    Hamilton Glaucoma Center, Dept. of Ophthalmology, University of California, San Diego, California
  • Christopher A. Girkin
    Ophthalmology, Univ of Alabama at Birmingham, Birmingham, Alabama
  • Jeffrey M. Liebmann
    Ophthalmology, NYU School of Medicine, New York, New York
    New York Eye and Ear Infirmary, New York, New York
  • Robert N. Weinreb
    Hamilton Glaucoma Center, Dept. of Ophthalmology, University of California, San Diego, California
  • Pamela A. Sample
    Hamilton Glaucoma Center, Dept. of Ophthalmology, University of California, San Diego, California
  • Michael H. Goldbaum
    Hamilton Glaucoma Center, Dept. of Ophthalmology, University of California, San Diego, California
  • Footnotes
    Commercial Relationships  Christopher Bowd, Pfizer Inc. (F); Intae Lee, None; Felipe A. Medeiros, Alcon Laboratories Inc. (F, C, R), Allergan Inc. (C, R), Carl Zeiss Meditec Inc. (F, R), Merck Inc. (F), Pfizer Inc. (F, C, R), Reichert Inc. (R); Madhusudhanan Balasubramanian, None; Linda M. Zangwill, Carl Zeiss Meditec Inc. (F), Heidelberg Engineering GmbH (F, R), Optovue Inc. (F), Topcon Medical Systems Inc. (F); Christopher A. Girkin, Alcon Laboratories Inc. (C), Allergan Inc. (C), Carl Zeiss Meditec Inc. (R), Heidelberg Engineering GmbH (R), Merck Inc. (R), Optovue Inc. (R), Pfizer Inc. (C), Topcon Medical Systems Inc. (R); Jeffrey M. Liebmann, Alcon Laboratories Inc. (C), Allergan Inc. (C), Carl Zeiss Meditec Inc. (F), Dyopsis Corp. (F, C), Heidelberg Engineering GmbH (F), Optovue Inc. (F, C), Pfizer Inc. (C), Topcon Medical Systems Inc. (F, C); Robert N. Weinreb, Alcon Laboratories Inc. (C), Allergan Inc. (C), Carl Zeiss Meditec Inc. (F, C), Heidelberg Engineering GmbH (F), Merck Inc. (C), Novartis (F), Optovue Inc. (F, C), Pfizer Inc. (C), Topcon Medical Systems Inc. (F); Pamela A. Sample, Carl Zeiss Meditec Inc. (F), Haag-Streit AG (F); Michael H. Goldbaum, None
  • Footnotes
    Support  NEI grants U10EY14267, R01EY19869, R01EY08208, R01EY11008, R01EY13959; Eyesight Foundation of Alabama; Alcon; Allergan; Pfizer; Merck; Santen; Corinne Graber Research Fund NY Glaucoma Research Inst.
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 4136. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Christopher Bowd, Intae Lee, Felipe A. Medeiros, Madhusudhanan Balasubramanian, Linda M. Zangwill, Christopher A. Girkin, Jeffrey M. Liebmann, Robert N. Weinreb, Pamela A. Sample, Michael H. Goldbaum; Predicting Glaucomatous Progression from Baseline HRT and SAP Measurements Using Relevance Vector Machine (RVM) Classifiers. Invest. Ophthalmol. Vis. Sci. 2011;52(14):4136.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose:
 

To determine if future glaucomatous progression can be predicted from baseline HRT and SAP measurements analyzed using RVM classifiers.

 
Methods:
 

271 eyes of 196 participants in the Diagnostic Innovations in Glaucoma Study (DIGS) or the African Descent and Glaucoma Evaluation Study (ADAGES) were included. Baseline HRT, SAP and optic disc stereophotographs were required within a six-month window. All eyes had normal SAP results at baseline and had a minimum of 5 SAP tests over time. Eyes were labeled as progressed (n=48) or non-progressed (n=223) during follow-up based on SAP Guided Progression Analysis "likely progression" or masked assessment of serial stereophotographs. Non-progressed eyes were stable by both assessment methods for a minimum of 4 years. Baseline HRT-measured topographic parameters (n=117) and baseline total deviation (TD) values from the 24-2 SAP test-grid (n=52) were selected from each eye. Ten-fold cross-validation was used to train and test RVM classifiers using the HRT and SAP features from unique subsets of the 271 study eyes. Areas under the receiver operating characteristic curve (AUROC), representing the average prediction accuracies, were calculated using full and optimized (using backward elimination) feature sets. AUROC results from HRT, SAP and HRT and SAP combined were compared to currently available HRT (GPS) and SAP (MD, PSD) global indices.

 
Results:
 

Results are presented in the table below.

 
Conclusions:
 

RVM analyses of baseline HRT and SAP measurements can predict eyes that will show glaucomatous progression with a higher accuracy than the HRT and SAP global indices investigated. In this study, HRT GPS and SAP MD did not predict progression any better than chance.  

 
Clinical Trial:
 

http://www.clinicaltrials.gov NCT00221897

 
Keywords: imaging/image analysis: clinical • visual fields 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×